[Physiopathology of the adrenergic receptors. II. Use of their inhibitors in endocrinology; indications and results].
D000328:Adult; D006145:Guanethidine / Q000627:therapeutic use; D006801:Humans; D006980:Hyperthyroidism / Q000188:drug therapy*; D008297:Male; D008750:Methyldopa / Q000627:therapeutic use; D010646:Phentolamine / Q000627:therapeutic use; D010673:Pheochromocytoma / Q000188:drug therapy*; D011299:Prenylamine / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D011984:Sensory Receptor Cells / Q000187:drug effects*; D013564:Sympathetic Nervous System / Q000187:drug effects*; D013565:Sympatholytics / Q000627:therapeutic use*
D013565:Sympatholytics; D008750:Methyldopa; D011433:Propranolol; D011299:Prenylamine; D010646:Phentolamine; D006145:Guanethidine
Physiopathologie des récepteurs adrénergiques. II. Utilisation de leurs inhibiteurs en endocrinologie; indications et résultats.